← Back to Search

Vitamin Supplement

4000 IU Vitamin D for Osler-Weber-Rendu Syndrome

Phase 2
Waitlist Available
Research Sponsored by St. Paul's Hospital, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months, and 6 months

Summary

This trial is testing if taking vitamin D regularly can help reduce the frequency and severity of nosebleeds in patients with HHT. Vitamin D might make blood vessels stronger and less likely to bleed. The study will compare different amounts of vitamin D to see which works best.

Eligible Conditions
  • Osler-Weber-Rendu Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months, and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 months, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Epistaxis Severity Score
Secondary study objectives
Change in Modified Lund-Kennedy Score

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 4000 IU Vitamin DExperimental Treatment1 Intervention
Group II: 1000 IU Vitamin DExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vit D
2016
Completed Phase 4
~1210

Find a Location

Who is running the clinical trial?

St. Paul's Hospital, CanadaLead Sponsor
46 Previous Clinical Trials
13,060 Total Patients Enrolled
~8 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top